| 000 | 01721 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250517125754.0 | ||
| 264 | 0 | _c20170620 | |
| 008 | 201706s 0 0 eng d | ||
| 022 | _a1471-2334 | ||
| 024 | 7 |
_a10.1186/s12879-016-2068-z _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSigera, Shamithra | |
| 245 | 0 | 0 |
_aSeroprevalence of Bordetella pertussis specific Immunoglobulin G antibody levels among asymptomatic individuals aged 4 to 24 years: a descriptive cross sectional study from Sri Lanka. _h[electronic resource] |
| 260 |
_bBMC infectious diseases _c12 2016 |
||
| 300 |
_a729 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntibodies, Bacterial _xblood |
| 650 | 0 | 4 |
_aBordetella pertussis _ximmunology |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aChild, Preschool |
| 650 | 0 | 4 | _aCross-Sectional Studies |
| 650 | 0 | 4 | _aEnzyme-Linked Immunosorbent Assay |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunization Schedule |
| 650 | 0 | 4 |
_aImmunoglobulin G _xblood |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aPertussis Toxin _ximmunology |
| 650 | 0 | 4 |
_aPertussis Vaccine _xtherapeutic use |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aSeroepidemiologic Studies |
| 650 | 0 | 4 |
_aSmoking _xadverse effects |
| 650 | 0 | 4 |
_aSri Lanka _xepidemiology |
| 650 | 0 | 4 |
_aWhooping Cough _xepidemiology |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aPerera, Jennifer | |
| 700 | 1 | _aRasarathinam, Jeyanthakumar | |
| 700 | 1 | _aSamaranayake, Dulani | |
| 700 | 1 | _aEdiriweera, Dileepa | |
| 773 | 0 |
_tBMC infectious diseases _gvol. 16 _gno. 1 _gp. 729 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/s12879-016-2068-z _zAvailable from publisher's website |
| 999 |
_c26656493 _d26656493 |
||